Wednesday March 18, 2020 0 comments
GOLDEN -- PharmaJet, maker of innovative, needle-free injection technology, announced it received a $9.6 million contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA).
DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding the use of needle-free technology to further progress promising nucleic acid vaccines, while also funding the development of PharmaJet's next generation needle-free devices.
The initial studies underway are focused on delivery of Venezuelan Equine Encephalitis Virus (VEEV) DNA Vaccines developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) using the PharmaJet systems.
The award is in response to the need for devices that can effectively deliver nucleic acid-based vaccines and are also compatible with military operations or a field environment.
Traditional electroporation devices posed a concern to military operations because of their bulky size, need for power supplies, patient discomfort and device sterilization issues.
The PharmaJet Needle-free Injection Systems are easy-to-use and optimized for field use. Multiple studies delivering DNA vaccines with PharmaJet systems have shown immunogenicity levels higher than with needle-syringe and comparable to electroporation.
The next generation needle-free devices will further enable the rapid development of nucleic acid vaccines and therapeutics.
"We are excited to be collaborating with the U.S. government to progress their vaccine development and next generation needle-free devices, which could include variable dose devices for additional pathogens,” said Chris Cappello, PharmaJet president and CEO.
“Our systems are already being used extensively in the field due to their ease-of-use, minimal training requirements and fast administration time."